Tarsus Pharmaceuticals, Inc. (TARS) stock
Close on Nov 12, 2026Market cap $3.37BP/E –Yield 0.00%
Tarsus Pharmaceuticals, Inc. grew revenue 105.2% to $606.33M over the twelve months to Jun 30, 2026. Free cash flow was $56.00M. At the latest close the market valued the company at $3.37B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.37B
- P/E ratio
- –
- Price to sales
- 5.56
- Price to book
- 9.73
- Dividend yield
- 0.00%
- Free cash flow yield
- 1.66%
Fundamentals
- Revenue
- $606.33M
- Net income
- -$46.48M
- EPS, diluted
- -$1.09
- Free cash flow
- $56.00M
- Book value per share
- $7.99
- Diluted shares
- 43M
Trading
- Next earnings
- Feb 22, 2027 (estimated, after the close)
- Previous close
- $76.76
- Open
- $76.81
- Day's range
- $74.91 – $77.88
- Volume
- 445,181
- Average volume (20 days)
- 968,559
- Index membership
- Russell 2000 (since Dec 2020), Russell 3000 (since Feb 2021)
- Beta (5 years)
- 0.64
- 52-week range
- $53.89 – $91.53
- RSI (14 days)
- 59.5
- Volatility (1 year)
- 44.8%
- Relative volume
- 0.48×
- WACC
- 8.1%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TARS | S&P 500 | Difference | TARS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.3% | -2.7% | +6.0 pts | ||
| 3 months | +9.8% | -1.7% | +11.6 pts | ||
| Year to date | -6.1% | +11.9% | −18.0 pts | ||
| 1 year | +2.8% | +12.0% | −9.2 pts | ||
| 3 years | +340.1% | +78.2% | +261.9 pts | +63.9% | +21.2% |
| 5 years | +182.8% | +73.2% | +109.5 pts | +23.1% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tarsus Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- News
- News
- News
About Tarsus Pharmaceuticals
Biological Products, (No Diagnostic Substances)
The company is a commercial-stage biopharmaceutical business focused on developing and commercializing therapeutics, primarily targeting eye care and infectious disease prevention. Its primary commercial product is XDEMVY, an FDA-approved prescription ophthalmic solution that treats Demodex blepharitis by eradicating Demodex mites through GABA-Cl channel inhibition. Additionally, the business develops investigational formulations using the lotilaner active pharmaceutical ingredient, including a topical gel candidate for ocular rosacea and an oral tablet candidate designed for Lyme disease prophylaxis. Its commercialized offerings serve patients presenting with mite infestations and ocular conditions, prescribed directly by eye care professionals such as ophthalmologists and optometrists.
Company profile, executives and historyTarsus Pharmaceuticals stock: common questions
What is Tarsus Pharmaceuticals's stock price?
TARS closed at $76.89 on Nov 12, 2026, up 0.17% on the day. Over the past 52 weeks it traded between $53.89 and $91.53.
What is Tarsus Pharmaceuticals's market cap?
Tarsus Pharmaceuticals was worth $3.37B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TARS's P/E ratio?
Tarsus Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.09), so it has no meaningful P/E ratio.
How much revenue does Tarsus Pharmaceuticals make?
Tarsus Pharmaceuticals reported revenue of $606.33M for the twelve months to Jun 30, 2026, up 105.2% from a year earlier.
Does Tarsus Pharmaceuticals pay a dividend?
No. Tarsus Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Tarsus Pharmaceuticals report earnings next?
Tarsus Pharmaceuticals is expected to report Q4 FY2026 results on Feb 22, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has TARS stock performed over the past year?
Including dividends, TARS returned +2.8% over the past year, against +12.0% for the S&P 500.
How many TARS shares are sold short?
6M shares were sold short at the latest FINRA report, 14.27% of the float, or 6.9 days of average trading volume.
Who are Tarsus Pharmaceuticals's competitors?
Companies most similar to Tarsus Pharmaceuticals by business, industry and size include BCRX, ARQT, MIRM, KRYS, ARDX.
See a number that looks wrong?